U.S. market Closed. Opens in 5 hours 19 minutes

FDMT | 4D Molecular Therapeutics, Inc. Stock Financials Income Statements Annual

(Stock Exchange: NASDAQ)
*Sign In to persist settings
Financial Year End2023-12-312022-12-312021-12-312020-12-312019-12-312018-12-312017-12-31
Revenue20.72M3.13M18.04M13.61M6.99M14.13M5.79M
Cost of Revenue97.10M3.88M3.02M53.04M38.72M18.36M13.57M
Gross Profit-76.37M-751.00K15.02M-39.43M-31.73M-4.23M-7.78M
Operating Expenses133.59M113.16M89.37M70.28M52.61M24.53M17.06M
Selling, General & Admin36.49M32.91M28.01M17.24M13.89M6.17M3.49M
Research & Development97.10M80.25M61.36M53.04M38.72M18.36M13.57M
Other Operating ExpensesN/A2.54M16.00K-181.00K-46.00K-2.00K-40.00K
Operating Income-112.87M-110.03M-71.33M-56.66M-50.76M-10.40M-11.27M
Other Expenses / Income12.03M2.54M16.00K-29.00K1.46M848.00K49.00K
Before Tax Income-100.84M-107.49M-71.32M-56.69M-49.31M-9.55M-11.22M
Income Tax ExpensesN/A-6.42M-3.02M-152.00K3.63M848.00K-89.00K
Net Income-100.84M-101.08M-68.30M-56.54M-52.94M-9.55M-11.22M
Interest ExpensesN/AN/AN/AN/AN/AN/AN/A
Basic Shares Outstanding39.13M32.35M27.73M26.68M26.49M12.52M14.84M
Diluted Shares Outstanding39.13M32.35M27.73M26.68M26.49M12.52M14.84M
EBITDA-107.12M-106.15M-68.31M-55.22M-44.62M-9.70M-10.65M
EBITDA Margin-516.90%-3,392.52%-378.72%-405.68%-638.75%-68.66%-183.87%
EBIT-100.84M-107.49M-71.32M-56.69M-49.31M-8.70M-11.31M
EBIT Margin-486.59%-3,435.41%-395.37%-416.49%-705.78%-61.59%-195.37%
Financial Year End2023-12-312022-12-312021-12-312020-12-312019-12-312018-12-312017-12-31
An error has occurred. This application may no longer respond until reloaded. Reload 🗙